Professor of Medicine, Indiana University
Gastroenterology
Dr. Naga Chalasani, MD
|
|
Give Review
Naga Chalasani works in the field of Gastroenterology. He attended Kakatiya Medical College NTR. He over the years received 9 awards: "Indianapolis Monthly", "ACG Governors Award for Excellence in Clinical Research", "Elected to American Society of Clinical Investigation (ASCI)", "Elected Member", "Young Investigator of the Year", "Alpha Omega Alpha", "DuPont Young Investigator's Award", "Poster finalist" and "Fellow (FACG)". Naga Chalasani is also a published physician. He has 58 publication published. The most recent publication is: Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Febuxostat-induced acute liver injury.
- Not routine screening, but vigilance for chronic liver Disease in patients with type 2 diabetes.
- Chronic liver injury induced by drugs: a Systematic review.
- Elevations in Circulating Methylated and Unmethylated Preproinsulin DNA in New-Onset Type 1 Diabetes.
- Response to levy.
- Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic Fatty liver Disease.
- Clinical and histologic features of azithromycin-induced liver injury.
- Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver Disease liver biopsies.
- Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
- Erratum to: Severe Drug-Induced Skin and Liver Injury from Rivaroxaban.
- Discrepancies in liver Disease labeling in the package inserts of commonly prescribed medications.
- Severe Drug-Induced Skin and Liver Injury from Rivaroxaban.
- Trials and tribulations in drug development for nonalcoholic steatoHepatitis.
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatoHepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
- Serum metabolic signatures of primary Biliary cirrhosis and primary sclerosing cholangitis.
- Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.
- Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals with Nonalcoholic Fatty Liver Disease.
- ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.
- Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine.
- Drug-induced hepatic steatosis.
- Slow but steady progress in a field with many knowledge gaps.
- Endoscopic Therapy with 2-Octyl-cyanoacrylate for the Treatment of Gastric Varices.
- Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease.
- Reliability of causality assessment for drug, herbal and dietary supplement hepatoxicity in the Drug-Induced Liver Injury Network (DILIN).
- Relationship Between Characteristics of Medications and Drug-Induced Liver Disease Phenotype and Outcome.
- Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from Benign portal vein thrombus in cirrhotic patients.
- De novo malignancy post-liver transplantation: a single center, population controlled study.
- Factors that Predict Short-Term Intensive Care Unit Mortality in Patients with Cirrhosis.
- Serum hepcidin levels are associated with obesity but not liver Disease.
- Drug-induced Liver Injury Caused by Intravenously Administered Medications: The Drug-induced Liver Injury Network Experience.
- Nonalcoholic fatty liver Disease: an emerging threat to obese and diabetic individuals.
- Pharmacokinetic and Pharmacodynamic Alterations in the Roux-en-Y Gastric Bypass Recipients.
- Prevalence and Morbidity Associated with Muscle Cramps in Patients with Cirrhosis.
- Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
- What Should We Recommend to Our Patients with NAFLD Regarding Alcohol Use?
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Stu...
- Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatoHepatitis: a pioglitazone versus vitamin E versus placebo for the trea...
- The diagnosis and management of non-alcoholic fatty liver Disease: Practice guideline by the american association for the study of liver Diseases, American College of ...
- Dyslipidemia in patients with nonalcoholic Fatty liver Disease.
- Initial experience with EUS-guided Tru-cut biopsy of Benign liver disease.
- Nonalcoholic fatty liver Disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
- Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
- Deep vein thrombosis and pulmonary embolism in Cirrhosis patients.
- HIV-1 Coinfection Profoundly Alters Intrahepatic Chemokine but Not Inflammatory Cytokine Profiles in HCV-Infected Subjects.
- Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis.
- Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.
- Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks.
- Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report.
- Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatoHepatitis: PIVENS trial design.
- Abnormal enhancing lesion of dentate nuclei causing neurologic symptoms induced by metronidazole toxicity.
- Severe liver injury after initiating therapy with atomoxetine in two children.
- Autoimmune Hepatitis triggered by statins.
- Complete reversal of glycogen hepatopathy with pancreas transplantation: two cases.
- Metabolic syndrome following liver transplantation is associated with major vascular events.
- Insulin resistance, Hepatitis C, and liver transplantation.
- Genetic Polymorphism of Cytochrome P450 4F2, Vitamin E Level and Histological Response in Adults and Children with Nonalcoholic Fatty Liver Disease Who Participated in...
- Screening Strategies for Nonalcoholic SteatoHepatitis in High-Risk Individuals: Trimming Away the Fat.
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Benign Neoplasm of the Digestive System
- Biliary Atresia
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- Indianapolis Monthly
- ACG Governor’s Award for Excellence in Clinical Research
- Elected to American Society of Clinical Investigation (ASCI)
- Elected Member
- Young Investigator of the Year
- Alpha Omega Alpha
- DuPont Young Investigator's Award
- Poster finalist
- Fellow (FACG)
Education
-
Emory University -
Kakatiya Medical College NTR
Drug Facts
| NPI NUMBER | 1588628002 | |
| NPPES Provider LastName | CHALASANI | |
| NPPES Provider FirstName | NAGA | |
| NPPES Provider ZIPCode | 462022859 | |
| NPPES Provider State | IN | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 407.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1588628002 |
| Last Name Of The Provider | CHALASANI |
| First Name Of The Provider | NAGA |
| View All |
Similar Doctors
|
|
Dr. Diane M. Settles, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Viplove Senadhi, DO |
|
|
Dr. Paul K. Haynes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad A. Al-Haddad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David N. Brown, MD |
|
|
Dr. Paul K. Frederick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ninad H. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan L. Fogel, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Stephen J. Carlson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shivi S. Siva, MD |